Andere Sprachen Biodesix, Inc.

Aktien

A2QFCN

US09075X1081

BDSX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
1,53 ^USD	+2,00 %		-10,53 %	-16,85 %

21.05.	Biodesix, Inc. präsentiert neue Daten zum Nodify XL2 Test auf der ATS-Jahrestagung 2024	CI
13.05.	BIODESIX, INC. : TD Cowen bleibt bei seiner Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Biodesix Named to Inc. Magazine's 2024 Best Workplaces	19.06.
Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”	18.06.
Biodesix to Participate in Two Investor Conferences in June	28.05.
Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting	22.05.
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting	21.05.
Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting	21.05.
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Earnings Flash (BDSX) BIODESIX Reports Q1 Revenue $14.8M, vs. Street Est of $14.2M	08.05.
Biodesix, Inc. Reports Unaudited Impairment Charges for the First Quarter Ended March 31, 2024	08.05.
Biodesix, Inc. Reaffirms Revenue Guidance for the Full Year 2024	08.05.
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management	08.05.
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference	07.05.
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024	24.04.
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting	09.04.
Biodesix, Inc. announced that it has received $34.999422 million in funding	09.04.
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement	08.04.
Top Midday Decliners	05.04.
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement	05.04.
Biodesix, Inc. announced that it expects to receive $34.999422 million in funding	05.04.
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center	25.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Biodesix, Inc.

Aktien

A2QFCN

US09075X1081

BDSX

Andere Sprachen

Filter